Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-Dose Chemotherapy and ABMT for Relapsed/Refractory NHL
NCT00002481Phase 2Unknown
- Sponsor
- St. Luke's Medical Center
- Start
- Mar 1990
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of etoposide and cyclophosphamide in non-Hodgkin lymphoma (NHL), sponsored by St. Luke's Medical Center. Primary endpoints: Toxicity of Regimen and Antitumor Activity. Status: unknown.
02
Drugs
etoposidecyclophosphamide
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT00002481.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002481.